Protein particulate detection issues in biotherapeutics development--current status.
about
Analyzing subvisible particles in protein drug products: a comparison of dynamic light scattering (DLS) and resonant mass measurement (RMM)Preparation, characterization, in vitro release and degradation of cathelicidin-BF-30-PLGA microspheres.Editor's Highlight: Subvisible Aggregates of Immunogenic Proteins Promote a Th1-Type Response.Biopharmaceutical formulations for pre-filled delivery devices.Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques.Surface modulation of polymeric nanocarriers enhances the stability and delivery of proteins and small molecules.Real-time observation of protein aggregates in pharmaceutical formulations using liquid cell electron microscopy.Evaluation of predictive tools for cell culture clarification performance.High-throughput analysis of sub-visible mAb aggregate particles using automated fluorescence microscopy imaging.Interference from Proteins and Surfactants on Particle Size Distributions Measured by Nanoparticle Tracking Analysis (NTA).A New Mixed All-Atom/Coarse-Grained Model: Application to Melittin Aggregation in Aqueous Solution.Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice.Challenges and new frontiers in analytical characterization of antibody-drug conjugates.Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions.Ophthalmic drug dosage forms: characterisation and research methods.
P2860
Q33574160-A3A2CEB2-CA59-4908-A357-E2B96DE399BDQ35194563-E699D733-AD36-48E9-A50C-5DB5596BB643Q37283495-D7557131-5873-4EB4-AB17-6B634B0B4B77Q38090687-6F50ED03-6403-4817-B3D1-4486609B1FB7Q40143552-82402163-150E-4A78-A377-A95A64910629Q40283549-9149B569-015A-4064-A1E8-D6C38636E2EEQ40994930-3F5ACD89-2400-43DC-B6FF-146067FC0FC5Q45995741-9FF4F952-F140-4412-AA16-0813990C5C92Q46376020-A034AF76-5114-49FB-8D3C-16E8ECE070EDQ47238029-A0534289-8150-429F-B0D2-B470004B2574Q47997409-7499E807-BD1A-4487-9D3D-64F1D15EBEF8Q48238341-A2C51B84-88C7-48FD-98D6-D850399713FEQ52401505-117EE213-C49F-41DD-9174-7F2D5E126520Q52680300-76C795F9-9A1D-449D-B464-B4A3ACD9C0D4Q55058119-F0E97777-A1FC-4DAA-AB11-6C29A4CA1C24
P2860
Protein particulate detection issues in biotherapeutics development--current status.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Protein particulate detection issues in biotherapeutics development--current status.
@en
type
label
Protein particulate detection issues in biotherapeutics development--current status.
@en
prefLabel
Protein particulate detection issues in biotherapeutics development--current status.
@en
P2860
P1433
P1476
Protein particulate detection issues in biotherapeutics development--current status
@en
P2093
Tapan K Das
P2860
P2888
P304
P356
10.1208/S12249-012-9793-4
P407
P50
P577
2012-05-08T00:00:00Z
P5875
P6179
1050938377